Sarah Gheuens - 01 Sep 2021 Form 3 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Medical Officer
Signature
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
Issuer symbol
AGIO
Transactions as of
01 Sep 2021
Net transactions value
$0
Form type
3
Filing time
10 Sep 2021, 21:32:06 UTC
Next filing
07 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGIO Common stock 3,462 01 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGIO Stock option (right to buy) 01 Sep 2021 Common stock 6,044 $38.72 Direct F1
holding AGIO Restricted stock units 01 Sep 2021 Common stock 1,667 Direct F2, F3
holding AGIO Restricted stock units 01 Sep 2021 Common stock 6,486 Direct F3, F4
holding AGIO Restricted stock units 01 Sep 2021 Common stock 9,375 Direct F3, F5
holding AGIO Stock option (right to buy) 01 Sep 2021 Common stock 3,243 $56.68 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on December 2, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 2, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2 The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.
F3 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4 The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
F5 The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022.
F6 This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.